Maven Securities LTD Buys 90,018 Shares of Apogee Therapeutics Inc. $APGE

Maven Securities LTD grew its stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 360.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,018 shares of the company’s stock after purchasing an additional 90,018 shares during the quarter. Apogee Therapeutics comprises about 0.3% of Maven Securities LTD’s portfolio, making the stock its 24th biggest holding. Maven Securities LTD’s holdings in Apogee Therapeutics were worth $15,266,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Apogee Therapeutics by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after buying an additional 694 shares in the last quarter. Millennium Management LLC raised its position in Apogee Therapeutics by 100.0% during the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after acquiring an additional 130,164 shares in the last quarter. Creative Planning acquired a new stake in Apogee Therapeutics in the second quarter valued at $392,000. Legal & General Group Plc lifted its stake in Apogee Therapeutics by 7.4% in the second quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock valued at $1,203,000 after acquiring an additional 1,907 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Apogee Therapeutics by 10,570.6% in the second quarter. Russell Investments Group Ltd. now owns 21,768 shares of the company’s stock valued at $945,000 after acquiring an additional 21,564 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

APGE has been the topic of several recent analyst reports. Craig Hallum set a $135.11 price objective on shares of Apogee Therapeutics and gave the stock a “hold” rating in a research note on Monday, June 22nd. Royal Bank Of Canada raised their target price on shares of Apogee Therapeutics from $82.00 to $97.00 and gave the company a “sector perform” rating in a research note on Monday, June 8th. Truist Financial lifted their price target on Apogee Therapeutics from $81.00 to $135.00 and gave the stock a “hold” rating in a report on Thursday, August 13th. Citigroup downgraded Apogee Therapeutics from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $125.00 to $135.00 in a research report on Tuesday, June 23rd. Finally, Guggenheim lowered Apogee Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Apogee Therapeutics currently has a consensus rating of “Hold” and an average target price of $126.77.

Apogee Therapeutics Price Performance

APGE stock opened at $135.07 on Wednesday. Apogee Therapeutics Inc. has a one year low of $35.39 and a one year high of $135.09. The stock has a market cap of $8.40 billion, a price-to-earnings ratio of -31.12 and a beta of 0.33. The company has a fifty day moving average price of $134.33 and a two-hundred day moving average price of $102.11.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, August 10th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.07). Research analysts anticipate that Apogee Therapeutics Inc. will post -4.47 EPS for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In related news, CEO Michael Henderson sold 80,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $132.54, for a total value of $10,603,200.00. Following the transaction, the chief executive officer owned 1,015,987 shares in the company, valued at approximately $134,658,916.98. This represents a 7.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $132.60, for a total transaction of $3,500,640.00. Following the completion of the transaction, the insider directly owned 179,248 shares in the company, valued at approximately $23,768,284.80. This represents a 12.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 137,400 shares of company stock worth $18,244,445. 24.30% of the stock is owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.